Viewing Study NCT06010212


Ignite Creation Date: 2025-12-26 @ 11:11 PM
Ignite Modification Date: 2026-02-24 @ 10:54 AM
Study NCT ID: NCT06010212
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-08-24
First Post: 2023-08-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module